O&G SAQs · Intrapartum care — medical comorbidity
Intrapartum care with existing medical conditions — structured SAQ (15 marks)
FRANZCOG-format structured SAQ on intrapartum care with existing medical conditions: the cardiac intrapartum plan, the diabetes glucose approach and postpartum insulin adjustment, the anticoagulation-to-neuraxial timing rules, and the immediate management of a seizure in labour. Per-sub-part marking rubric included.
On this page
Study tools
Target exams
How this SAQ is marked
Twelve SAQs, 180 marks, two 2-hour papers — roughly 15 marks and 20 minutes each. This topic is examined for specifics: the mWHO class, the glucose approach, the anticoagulation clock, and "never ergometrine." Write in short labelled points, answer the sub-part you are asked, and quote the number that earns the mark. [4]
Reveal model answer and mark schemeShowHide
(a) The cardiac intrapartum plan (6 marks)
One mark per component; the third-stage drug and the mode-of-birth default are each worth a mark. [4]
- Find and follow the written multidisciplinary plan — agreed antenatally by obstetrics, cardiology and anaesthesia; the default for class III is planned vaginal birth in a centre with cardiology and intensive care on site (ROPAC found planned caesarean was not beneficial for most cardiac women).[5][4]
- Position: left lateral, avoid supine; continuous pulse oximetry and strict fluid balance.[4]
- Analgesia: early epidural, placed slowly with careful fluid management — it blunts the catecholamine and afterload surge of pain and is protective for most lesions.[4]
- Second stage: assisted (operative) second stage to shorten the bearing-down effort in a fixed-output lesion.[4]
- Third-stage drug: oxytocin, given slowly and dilute; ergometrine is contraindicated because it causes an acute afterload rise that can precipitate pulmonary oedema.[4]
- Postpartum surveillance: high-dependency observation for 72 hours, because the postpartum fluid mobilisation is the danger window and late heart failure is the killer.[4]
(b) Diabetes in labour (3 marks)
One mark per point. [6]
- Tight intrapartum capillary glucose control, monitored hourly through labour (continuous monitoring where available). The standard target range is 4 to 7 mmol per litre, the level achieved in the randomised comparison of intrapartum regimens.[7]
- Insulin and dextrose infusion titrated to keep her in range; a rotating-fluids regimen is a reasonable alternative and was comparable to an insulin drip (mean glucose about 5.8 mmol per litre) with similar neonatal outcomes.[7]
- Halve the insulin infusion immediately after birth — insulin requirements fall off a cliff as the placental insulinase is delivered; switch the type 1 diabetic back towards her prepregnancy regimen and arrange a neonatal hypoglycaemia alert.[6][7]
(c) Anticoagulation and the epidural catheter (3 marks)
One mark for each timing rule; stating the rationale earns the third. [10]
- Catheter removal must wait 24 hours after the last therapeutic enoxaparin dose, because therapeutic-dose low-molecular-weight heparin carries a real risk of spinal epidural haematoma if the window is breached.[10]
- The next enoxaparin dose waits 4 hours after catheter removal.[10]
- Rationale: LMWH is only partially reversed by protamine and has a longer half-life than unfractionated heparin, which is why the timing rules exist — a systematic review found no case of obstetric spinal epidural haematoma when they are kept, and the whole point is to keep them rather than assume them away.[9][10]
(d) Seizure in labour (3 marks)
One mark per point; treating first as eclampsia if there is doubt earns credit. [11]
- Airway, left lateral position, call for help, time the seizure.[11]
- For ongoing seizure give a benzodiazepine (for example intravenous lorazepam 4 mg, repeated once after 10 minutes).[11]
- Rule out eclampsia with the blood pressure, reflexes and urinalysis; give magnesium sulphate if eclampsia is possible — it is safer to treat first and clarify the diagnosis afterwards. Continue her antiseizure medication and arrange one-to-one care.[11]
References8ShowHide
- [4]Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J, 2018.PMID 30165544
- [5]Ruys TP, Roos-Hesselink JW, Pijuan-Domènech A, et al. Is a planned caesarean section in women with cardiac disease beneficial? Heart, 2015.PMID 25539946
- [6]Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet, 2017.PMID 28923465
- [7]Rosenberg VA, Eglinton GS, Rauch ER, Skupski DW Intrapartum maternal glycemic control in women with insulin requiring diabetes: a randomized clinical trial of rotating fluids versus insulin drip. Am J Obstet Gynecol, 2006.PMID 16893507
- [8]Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv, 2018.PMID 30482767
- [9]Leffert LR, Dubois HM, Butwick AJ, Carvalho B, Houle TT, Landau R Neuraxial Anesthesia in Obstetric Patients Receiving Thromboprophylaxis With Unfractionated or Low-Molecular-Weight Heparin: A Systematic Review and Meta-analysis. Anesth Analg, 2017.PMID 28628578
- [10]Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med, 2018.PMID 29561531
- [11]Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Allen Hauser W, Wiebe S, Gronseth GS, Thurman D, Meador KJ, Koppel BS Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia, 2009.PMID 19496807